Results 1 to 10 of about 1,027,416 (202)
Carbapenem resistant Enterobacterales in the United Arab Emirates: a retrospective analysis from 2010 to 2021 [PDF]
BackgroundCarbapenem-resistant Enterobacterales (CRE) are spreading in the United Arab Emirates (UAE) where their dissemination is facilitated by international travel, trade, and tourism.
Jens Thomsen +10 more
doaj +6 more sources
Metallo-beta-lactamases (MBLs) are enzymes that break down carbapenem antibiotics, leading to carbapenem-resistant organisms. Carbapenemase-resistant Enterobacterales (CRE) is one of them. Outbreaks of CRE infection can occur in healthcare facilities and
Kentarou Takei +9 more
doaj +2 more sources
Introduction: Interest in fosfomycin, an old antibiotic, has been reignited because of the use of its intravenous formulation (fosfomycin sodium) in resistant infections.
Yakup GEZER +4 more
doaj +2 more sources
In this study, the presence of blaNDM-1 gene in carbapenem-resistant Enterobacterales obtained from various clinical specimen of a University Hospital in Turkey between the years 2014-2019, has been investigated.
Merih Simsek, Cengiz Demir, Esra Seker
doaj +2 more sources
Metallo-β-lactamase mediated resistance and Class 1 integron in carbapenem-resistant Enterobacterales isolates from the clinical specimens of Nepal [PDF]
Background Carbapenem-resistant Enterobacterales (CRE) pose an escalating public health threat due to their limited therapeutic options and their potential for rapid dissemination in healthcare settings. Mobile genetic elements (MGEs), such as integrons,
Manisha Shrestha +6 more
doaj +2 more sources
Increase in blaNDM among Carbapenemase-Producing, Carbapenem-Resistant Enterobacterales, United States, 2016–2023 [PDF]
We report an increase of blaNDM among carbapenemase-producing, carbapenem-resistant Enterobacterales collected in the United States through the Emerging Infections Program’s Multi-site Gram-negative Surveillance Initiative.
Uzma Afroz Ansari +9 more
doaj +2 more sources
In recent years, a wide range of clinical infections are being caused by carbapenem-resistant Enterobacterales, Acinetobacter baumannii and Pseudomonas aeruginosa. This is a matter of great concern, as carbapenem-resistant infections have fewer treatment
Gaurav Verma +6 more
doaj +1 more source
In vitro activity of ceftazidime/avibactam against Gram-negative strains in Colombia 2014–2018
: Objectives: Ceftazidime/avibactam (CAZ/AVI) has shown in vitro activity against multidrug-resistant (MDR) Gram-negative bacteria, especially Enterobacterales and carbapenem-resistant Pseudomonas aeruginosa.
Elkin V. Lemos-Luengas, MD, PhD +3 more
doaj +1 more source
Novel β-lactam–β-lactamase inhibitor combinations (BLBLIs) are in clinical development for the treatment of infections caused by carbapenem-resistant and difficult-to-treat resistant (DTR) (defined as resistance to all tested β-lactams and ...
Yan Guo +10 more
doaj +1 more source
Objective: To determine the mechanism of Carbapenem resistance, type of Carbapenemase produced and in vitro efficacy of Ceftazidime-Avibactam (CAZ-AVI) and Meropenem-Vaborbactam (MEV) against Carbapenem-resistant Enterobacterales and in vitro efficacy ...
Fatima Ali +5 more
doaj +1 more source

